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SREBP1-dependent de novo fatty 
acid synthesis gene expression is 
elevated in malignant melanoma 
and represents a cellular survival 
trait
Su Wu  1,2,3 & Anders M. Näär1,2,4
de novo fatty acid biosynthesis (DNFA) is a hallmark adaptation of many cancers that supports survival, 
proliferation, and metastasis. Here we elucidate previously unexplored aspects of transcription 
regulation and clinical relevance of DNFA in cancers. We show that elevated expression of DNFA genes 
is characteristic of many tumor types and correlates with poor prognosis, especially in melanomas. 
Elevated DNFA gene expression depends on the SREBP1 transcription factor in multiple melanoma 
cell lines. SREBP1 predominantly binds to the transcription start sites of DNFA genes, regulating their 
expression by recruiting RNA polymerase II to promoters for productive transcription elongation. 
We find that SREBP1-regulated DNFA represents a survival trait in melanoma cells, regardless of 
proliferative state and oncogenic mutation status. Indeed, malignant melanoma cells exhibit elevated 
DNFA gene expression after the BRAF/MEK signaling pathway is blocked (e.g. by BRAF inhibitors), 
and DNFA expression remains higher in melanoma cells resistant to vemurafenib treatment than in 
untreated cells. Accordingly, DNFA pathway inhibition, whether by direct targeting of SREBP1 with 
antisense oligonucleotides, or through combinatorial effects of multiple DNFA enzyme inhibitors, 
exerts potent cytotoxic effects on both BRAFi-sensitive and -resistant melanoma cells. Altogether, 
these results implicate SREBP1 and DNFA enzymes as enticing therapeutic targets in melanomas.
Cancer cells characteristically achieve hallmark traits that facilitate proliferation, survival, and metastasis1–3. One 
hallmark adaptation is de novo fatty acid synthesis (DNFA), metabolic conversion of carbohydrates into lipids 
via acetyl-CoA and NADPH with the aid of multiple lipogenic enzymes, including ATP citrate lyase (ACLY), 
acyl-coenzyme A synthetase 2 (ACSS2), acetyl-CoA carboxylase (ACACA), fatty acid synthase (FASN), and 
stearoyl-CoA desaturase (SCD)4. DNFA occurs in cancer cells and certain types of healthy cells5. In hepato-
cytes, DNFA activity is primarily regulated at the transcriptional level of mRNAs encoding DNFA enzymes6, in 
response to dietary lipids (e.g. polyunsaturated fatty acids7–9) and hormonal cues such as insulin10. DNFA also 
increases during normal embryonic development and adipogenesis to satisfy elevated lipid demands during cell 
proliferation and fat storage processes, respectively11,12.
The transcription factor sterol regulatory element-binding protein 1 (SREBP1) plays a central role in controlling 
DNFA gene expression, and, by extension, cellular FA/lipid production13,14. There are two major mechanisms involved 
in SREBP1 regulation: mRNA expression and proteolytic processing15. The SREBF1 gene encodes a SREBP1 precursor 
protein embedded in the endoplasmic reticulum membrane through two transmembrane domains16–18. In response 
to depletion of cellular and membrane lipids, its nuclear form (nSREBP1) is released by site 1 and site 2 proteases19–21, 
translocates into the nucleus and binds to target gene promoters. nSREBP1 activates the transcription of DNFA genes, 
in concert with other transcription factors such as LXR22, USF123, NFY124 and SP125, and co-activators including 
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MED1526 and CREBBP27. nSREBP1 also participates in activation of SREBF1 mRNA expression by binding to its own 
promoter28, thus the levels of DNFA mRNAs parallel the changes in SREBF1 expression13.
Elevated DNFA has been demonstrated in many tumor types29. Prevailing thought holds that hallmark traits, 
such as DNFA, emerge via pro-survival signaling pathways driven by oncogene and tumor suppressor altera-
tions30–33. Supposed tumor cell dependence on a single oncogenic driver or pathway to sustain proliferation and/
or survival has guided the development of targeted cancer therapies34,35. However, in clinical settings, tumors 
harbor highly diverse genetic alterations and exhibit stochastic evolution36, which often limits the prognostic 
and therapeutic value of that supposition37–40. Resistance to targeted therapies related to reactivation or bypass of 
downstream signaling pathways is common41. It is unclear whether oncogene alterations maintain hallmark traits 
such as DNFA in malignant tumors. Furthermore, potential interaction between oncogenic drivers and DNFA 
has not been fully investigated, especially under the selective pressure of targeted therapies.
We show here that elevated expression of key DNFA enzymes such as SCD is associated with poor prognosis 
in cancers, including melanomas. We demonstrate the molecular mechanism by which SREBP1 controls DNFA 
gene transcription in melanoma cells, revealing a regulatory role for RNA polymerase II pause/release. Our cel-
lular analyses further reveal crucial roles for elevated DNFA gene expression in cell proliferation and survival, 
regardless of whether they are sensitive or resistant to targeted therapies (e.g., BRAF inhibitors).
Results
Expression and prognostic value of DNFA genes in cancers. Elevated lipogenic enzyme activities 
have been reported in colon, breast and prostate cancers42–44. Positive correlation of RNA and protein abun-
dance of lipogenic enzymes was confirmed in breast cancer biopsies from Clinical Proteomic Tumor Analysis 
Consortium (CPTAC) (Supplemental Table 1)45. We analyzed the expression of five major DNFA enzymes SCD, 
FASN (Fig. 1a,b), ACLY, ACSS2 (Supplementary Fig. 1a,b) and ACACA (Supplementary Fig. 2a) using RNA-Seq 
Figure 1. Elevated expression of DNFA genes is prevalent in many cancers, including melanomas, and has 
prognostic value. (a,b) Expression of SCD and FASN genes was compared using RSEM normalized RNA-Seq 
data from 10,210 tumor samples downloaded from The Cancer Genome Atlas (TCGA). The box and whisker 
plots represent gene expression in 30 TCGA cancer types. (c,d) We divided patients into two groups based on 
the ranking of SCD mRNA expression from their tumor biopsies. Differences in overall survival rates were 
computed between patients with top 20% SCD RNA-Seq counts in their tumor samples and those with bottom 
20% SCD expression, as Kaplan-Meier plots in all cancer patients and skin cancer patients (SKCM) from the 
TCGA dataset. (e) The boxplot shows average mRNA reads of SCD in 4,645 single cells from tumor samples of 
19 melanoma patients (GSE72056). SCD expression was compared between malignant and nonmalignant cells.
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data from 30 diverse cancer types in The Cancer Genome Atlas (TCGA). We found that DNFA enzyme expression 
varies widely among cancers. Four DNFA enzymes – SCD, FASN, ACLY and ACSS2 – exhibit the highest levels of 
mRNA expression in skin cutaneous melanoma (SKCM) compared to other tumor types, whereas expression of 
ACACA is less elevated in melanomas (Supplementary Fig. 2a). We observed relatively low expression of mRNAs 
encoding HMGCS1 and HMGCR, two rate-limiting enzymes in the de novo cholesterol synthesis (DNCS) path-
way46 in melanomas. These results indicate that elevated DNFA expression is prevalent among tumors, signifi-
cantly more so in melanomas than in most others.
To relate elevated DNFA expression with disease progression, we examined its prognostic value using Kaplan-Meier 
analysis. We divided patients into two groups based on the DNFA gene expression from their tumor biopsies and 
compared overall survival rates. We found that high expression of SCD (Fig. 1c and Supplementary Fig. 2d,g), FASN 
(Supplementary Figs 1c and 2e,h) and ACACA (Supplementary Fig. 2b,f) significantly correlates with poor prognosis in 
all cancers considered collectively. The only exceptions we observed were ACLY (Supplementary Fig. 1e) and ACACA 
specifically with a top 10% versus bottom 10% expression cutoff (Supplementary Fig. 2i). Elevated mRNA expression 
of SCD (Fig. 1d), FASN, ACLY (Supplementary Fig. 1d,f) and ACACA (Supplementary Fig. 2c) each correlates with 
poor prognosis in SKCM. We observed for HMGCS1 but not HMGCR that higher expression significantly correlates 
with poor survival in all tumor types combined (Supplementary Fig. 3c,e), using 20% as cutoff, however, this was not 
observed in SKCM (Supplementary Fig. 3d,f).
Melanoma is the most aggressive skin cancer type. To control for potential tissue-specific upregulation, we 
first compared SCD expression in healthy tissues using RNA-Seq data from the Genotype-Tissue Expression 
(GTEx) database47. There, skin SCD expression is low (Supplementary Fig. 4a); yet among tumor tissues, skin 
SCD expression is elevated (Fig. 1a). This contrasts with, for example, the liver, which exhibits relatively high 
SCD expression among healthy (Supplementary Fig. 4a) and tumor tissues (Fig. 1a). We then compared SCD, 
ACLY and HMGCS1 expression using normalized RNA-Seq data from the SKCM group in TCGA and the normal 
skin tissue group in GTEx. SCD and ACLY mRNA expression is markedly elevated in SKCM versus healthy skin 
tissues (Supplementary Fig. 4b,c), while HMGCS1 is higher in the healthy tissues (Supplementary Fig. 4d). We 
performed principal component analysis (PCA) on RNA-Seq data of DNFA genes from skin tumors and healthy 
skin tissues (Supplementary Fig. 4e,f), and found that skin tumors are distinct from healthy skin samples. SCD 
expression strongly correlates with principal component 1 (PC1) towards skin tumors. Long-chain acyl-CoA 
synthetase (ACSL1) is a dual function enzyme in DNFA and fatty acid oxidation pathways with low abundance 
in tumors4. When its expression is combined with other DNFA genes in PCA, ACSL1 expression strongly corre-
lates with PC1 towards healthy tissues and results in better separation of skin tumors from healthy skin tissues 
(Supplementary Fig. 4e,f). In a separate PCA, DNCS expression, particularly HMGCS1, strongly correlates with 
PC1 (Supplementary Fig. 4g). Supplementary Fig. 4e–g suggests difference in lipogenic activities between skin 
tumors and healthy skin tissues.
Melanomas are transformed from benign, melanocytic nevi, with proliferation of melanocytes commonly 
triggered by BRAFV600E-activating mutation48. To confirm cancer-selective elevation in expression, we com-
pared the DNFA gene expression between malignant melanoma biopsies and benign melanocytic nevus sam-
ples (Supplementary Fig. 5a–d). We observed significantly elevated DNFA gene expression in malignant 
melanomas. We further analyzed single cell RNA-Seq data from melanoma samples49. High expression of SCD, 
FASN, and ACACA was confined to malignant cells, with low expression in healthy adjacent tissue (Fig. 1e and 
Supplementary Fig. 5e–h). Somatic mutations of BRAF and NRAS are associated with about 50% and 15% of 
melanomas, respectively48. BRAF and NRAS mutations, while being well-known risk factors and drivers of cancer 
onset, have limited prognostic significance for overall survival of melanoma patients50. There is no significant cor-
relation between DNFA enzyme expression and common oncogenic driver mutations in SKCM (Supplementary 
Fig. 6a–l), suggesting that elevated DNFA expression in malignant melanomas is mechanistically unrelated to 
BRAF and NRAS mutation status.
SREBP1 contributes to elevated DNFA gene expression in melanoma cells. To test whether SREBP1 
drives elevated DNFA enzyme expression in melanomas, we depleted the SREBP1 mRNA (SREBF1) with antisense 
oligonucleotides (ASOs) and siRNAs in HT-144 cells. SREBF1 depletion with siRNA and ASO agents was accompanied 
by decreasing protein levels of SREBP1 and DNFA enzymes (Fig. 2a). The pooled siRNA and ASO agents effectively 
depleted both the cytoplasmic precursor and the mature nuclear SREBP1 (Fig. 2b,c). Among six tested ASOs targeting 
SREBF1, ASO-1 and ASO-4 are more potent than single or pooled siRNAs for SREBF1, as 5 nM of ASOs inhibited 
DNFA mRNA production as effectively as 50 nM of siRNAs (Supplementary Fig. 7b–f), even when siRNAs decreased 
the level of SREBF1 mRNA more than ASOs (Supplementary Fig. 7a). ASOs may also engage in steric translation inhi-
bition of SREBF1 mRNA51, which could potentially contribute to their greater potency. We found that ASO-4 inhibits 
DNFA gene expression commensurately with dosage (Supplementary Fig. 7g).
To evaluate potential activators of DNFA expression, we depleted SREBF1, SREBF2, and co-activators 
MED15 and CREBBP28 with siRNAs, and examined DNFA expression across three melanoma cell lines: HT-144 
(Fig. 2d,e), A375 (Supplementary Fig. 7i,j) and MEL-JUSO (Supplementary Fig. 8a,b). We observed a similar 
range of mRNA reductions (50–70%) for most DNFA enzymes after SREBF1 depletion (Fig. 2d, Supplementary 
Figs 7i and 8a). Depletion of MED15 and CREBBP individually or together impacts DNFA gene expression, but to 
a lesser extent than SREBF1 depletion (Supplementary Figs 7i and 8a). SREBF2 depletion exerts potent effects on 
the expression of the DNCS genes HMGCS1 and HMGCR in HT-144 and A375 cells (Supplementary Fig. 7h,k), 
in line with previous studies in hepatocytes52. SREBF2 also affects DNFA enzyme expression, especially in con-
cert with SREBF1 depletion (Supplementary Fig. 8a–d). The role of SREBP2 in regulation of DNFA genes may be 
transitive via SREBP153, since SREBF1 expression decreases after SREBF2 depletion (Fig. 2e); or it may be acting 
in a partially redundant manner54. Thus, we confirmed the transcription regulatory role of SREBP1 in promoting 
DNFA gene expression in multiple melanoma cell lines.
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To understand the dynamics of DNFA gene expression, we performed a time-course study in A375 cells cul-
tured under SREBP1-activating conditions (1% ITS medium)55. FASN and SCD displayed increased expression at 
consecutive time points (Supplementary Fig. 8c–f). SREBF1 depletion by siRNA blocked DNFA gene activation 
on days 3 and 5, whereas DNFA enzyme protein (Fig. 2f) and mRNA levels (Fig. 2g,h) were elevated in response 
to overexpression of nSREBP1a, the abundant isoform in proliferating embryonic cells and in cancers, as well as 
nSREBP1c, which is the predominant isoform in adult liver and adipose tissues56. With a longer transactivation 
domain, nSREBP1a interacts more avidly with co-activators and thus exhibits stronger transcription activity than 
nSREBP1c27,57. Consistently, we observed higher expression of DNFA genes after overexpressing nSREBP1a than 
nSREBP1c. These results indicate that SREBP1 expression controls DNFA gene expression in melanoma cells.
SREBP1 directly regulates DNFA pathway genes through RNAP II recruitment and productive 
elongation. To characterize the transcriptome changes after SREBF1 depletion, we carried out RNA-Seq 
analysis after SREBF1 depletion with pooled siRNAs and individual ASOs in HT-144 cells, followed by PCA 
on RNA-Seq data. To identify the possible off-target effect of the ASOs, we performed RNA-Seq analyses on 
pc
DN
A3
Fla
g-n
SR
EB
F1
c
Fla
g-n
SR
EB
F1
a
0
50
100
150
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
**
**
SREBF1
h
pc
DN
A3
Fla
g-n
SR
EB
F1
c
Fla
g-n
SR
EB
F1
a
pc
DN
A3
Fla
g-n
SR
EB
F1
c
Fla
g-n
SR
EB
F1
a
pc
DN
A3
Fla
g-n
SR
EB
F1
c
Fla
g-n
SR
EB
F1
a
pc
DN
A3
Fla
g-n
SR
EB
F1
c
Fla
g-n
SR
EB
F1
a
pc
DN
A3
Fla
g-n
SR
EB
F1
c
Fla
g-n
SR
EB
F1
a
0.0
0.3
0.6
0.9
1.2
1.5
1.8
2.1
2.4
2.7
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n
ACSS2 ACLY ACACA FASN SCD
**
****
ns
*
ns
*
ns
**
*
**
g
a
flSREBP1
SCD
FASN
ACSL1
ACTB
siS
RE
BF
1-0
5
siS
RE
BF
1-0
6
siS
RE
BF
1-0
7
siS
RE
BF
1-0
8
siN
eg
ati
ve
siS
RE
BF
1 p
oo
l
Mo
ck
AS
O-
1
AS
O-
2
AS
O-
3
AS
O-
4
AS
O-
5
AS
O-
6
AS
O-
Ne
g
siRNAs (50 nM)ASOs (5 nM)
150
50
250
75
50
100
50
37
(KDa)
siN
eg
ati
ve
siS
RE
BF
1
siS
RE
BF
2
siM
ED
15
siC
RE
BB
P
siN
eg
ati
ve
siS
RE
BF
1
siS
RE
BF
2
siM
ED
15
siC
RE
BB
P
siN
eg
ati
ve
siS
RE
BF
1
siS
RE
BF
2
siM
ED
15
siC
RE
BB
P
siN
eg
ati
ve
siS
RE
BF
1
siS
RE
BF
2
siM
ED
15
siC
RE
BB
P
siN
eg
ati
ve
siS
RE
BF
1
siS
RE
BF
2
siM
ED
15
siC
RE
BB
P
siN
eg
ati
ve
siS
RE
BF
1
siS
RE
BF
2
siM
ED
15
siC
RE
BB
P
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
ge
ne
 e
xp
es
si
on
ACSS2 ACLY FASN SCD
****
************
********
****
**** ****
************
****
****
****
****
ACACA ACSL1
****
****
****
****
********
********
d 
AS
O-
1
AS
O-
2
AS
O-
3
AS
O-
4
AS
O-
5
AS
O-
6
AS
O-
Ne
g
AS
O-
1
AS
O-
2
AS
O-
3
AS
O-
4
AS
O-
5
AS
O-
6
AS
O-
Ne
g
(5 nM)
flSREBP1
cytoplasmic extract nuclear extract
nSREBP1
ACTB
150
100
75
50
50
37
20
15
Histone H3
(KDa)
b
siN
eg
ati
ve
siS
RE
BF
1
siS
RE
BF
2
siM
ED
15
siC
RE
BB
P
siN
eg
ati
ve
siS
RE
BF
1
siS
RE
BF
2
siM
ED
15
siC
RE
BB
P
siN
eg
ati
ve
siS
RE
BF
1
siS
RE
BF
2
siM
ED
15
siC
RE
BB
P
siN
eg
ati
ve
siS
RE
BF
1
siS
RE
BF
2
siM
ED
15
siC
RE
BB
P
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
ge
ne
 e
xp
es
si
on
SREBF1 SREBF2 MED15 CREBBP
****
****
****
****
****
****
********
****
****
****
****
****
****
****
****
e 
siS
RE
BF
1-0
5
siS
RE
BF
1-0
6
siS
RE
BF
1-0
7
siS
RE
BF
1-0
8
siN
eg
ati
ve
siS
RE
BF
1 p
oo
l
siS
RE
BF
1-0
5
siS
RE
BF
1-0
6
siS
RE
BF
1-0
7
siS
RE
BF
1-0
8
siN
eg
ati
ve
siS
RE
BF
1 p
oo
l
(50 nM)Mo
ck
Mo
ck
cytoplasmic extract nuclear extract
flSREBP1
nSREBP1
ACTB
150
100
75
50
50
37
20
15
Histone H3
(KDa)
c
flSREBP1
FASN
ACSS2
ACTB
pc
DN
A3
Fla
g-n
SR
EB
P1
a
Fla
g-n
SR
EB
P1
c
nSREBP1
150
100
(KDa)
75
250
75
50
f
Figure 2. SREBP1 regulates the elevated DNFA gene expression in melanoma cells. (a) HT-144 cells were 
treated with ASOs, individual siRNA agents or pooled siRNAs (all individual agents combined) to deplete 
SREBP1 in 1% ITS medium. Total cell lysates were assayed with immunoblot by the indicated antibodies. HT-
144 cells were transfected with (b) ASOs, (c) individual siRNA agents or pooled siRNAs in 1% ITS medium. 
Nuclear and cytoplasmic extracts were isolated for Western blot analysis of full length (fl) and nuclear (n) 
SREBP1 protein after treatment. (d,e) HT-144 cells were transfected with the pooled siRNAs (50 nM) in 
1% ITS medium for three days to deplete SREBF1, SREBF2, MED15 or CREBBP. RT-qPCR assay of mRNA 
shows relative expression of DNFA enzymes from siRNAs treatment groups to that of negative control siRNA 
treatment (siNegative). (f–h) HT-144 cells were transfected with plasmids carrying the transcriptionally active 
N-terminal portion of SREBP1a (nSREBP1a), N-terminal portion of SREBP1c (nSREBP1c) or empty vector 
(pcDNA3) for two days. (f) Total cell lysate was analyzed by Western blot assay using the indicated antibodies. 
(g,h) mRNAs were analyzed with RT-qPCR assay. The bar graphs show the relative expression of DNFA 
enzymes to that of pcDNA3 (control) transfection group. Data are expressed as mean ± SD and quantified from 
triplicates. One-way ANOVA tests were performed. ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; 
****P < 0.0001.
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two constructs that target different sequence regions of SREBF1 mRNA: ASO-1 and ASO-4. The two principal 
components (PCs) in the PCA biplot represent over 70% of the overall gene expression changes (Fig. 3a and 
Supplementary Fig. 9a). SREBF1 and SCD are among the top six contributors to data separation and they align 
with PC2 (Fig. 3a, Supplementary Fig. 9b). SREBF1 siRNA, ASO-1 and ASO-4 produced similar vertical sepa-
rations to all negative controls in PC2 (Fig. 3a), and they all reduced expression of FASN and SCD compared to 
negative controls (Supplementary Fig. 9e–g). These results indicate that the most profound effects after SREBF1 
depletion by both ASOs and siRNA are on DNFA genes. ASO-1 has significant lateral separation from ASO-4 
and SREBF1 siRNA on PC1 (Fig. 3a). The changes in SPIRE1 and USP9X expression are the major contributors 
to PC1 (Supplementary Fig. 9c) and are only affected by ASO-1 (Supplementary Fig. 9h,i). This result indicates 
that ASO-1 has specific off-target effects on SPIRE1 and USP9X. Multiple negative controls are grouped together, 
and ASO-4 is close to SREBF1 siRNA on the PCA biplot, consistent with the results from hierarchical clustering 
analysis of the same RNA-Seq dataset (Supplementary Fig. 9d). Hence, ASO-4 has similar specificity as pooled 
SREBF1 siRNAs for SREBF1 depletion.
To explore the overall biological pathways affected by SREBF1 depletion, we examined differentially expressed 
genes (DEGs) in the RNA-Seq dataset (siSREBF1 group vs siNegative group) (Supplementary Fig. 9j). Using 
gene-set enrichment analyses (GSEA) with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and 
gene ontology (GO) terms on DEGs, we determined that the downregulated genes after SREBF1 depletion are pri-
marily involved in fatty acid biosynthesis and lipid metabolism (Fig. 3b, and Supplementary Fig. 9k), as expected. 
Cellular inflammatory response pathways are significantly enriched in upregulated genes after SREBF1 depletion 
(Fig. 3c, and Supplementary Fig. 9l), including Toll like receptor and tumor necrosis factor (TNF) signaling path-
ways that mediate cytotoxicity58.
To assess the direct regulatory roles of SREBP1 on target genes in cancers, we analyzed public ChIP-Seq data 
for SREBP1 from lung cancer, breast cancer and chronic myeloid leukemia (CML) cell lines. ChIP-Seq peaks 
primarily localize at the proximal promoter regions around TSS (Supplementary Fig. 10a,b). De novo motif 
sequences identified from SREBP1 ChIP-Seq peaks match the known SREBP1 binding motif (Supplementary 
Fig. 10c). High DNFA gene expression was observed in lung and breast cancers (Fig. 1a). We identified genes 
that are present in SREBP1 ChIP-Seq data from both lung cancer line A549 and breast cancer line MCF7 
(Supplementary Fig. 10d), and that are also DEGs in our RNA-Seq data. We reasoned that the “overlapping” 
genes common to all three data sets are likely regulated directly by SREBP1. We therefore performed functional 
network analysis on this subset. This analysis revealed genes in many pathways including the PI3K/AKT pathway 
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Figure 3. SREBP1 regulates DNFA pathway genes through RNAP II recruitment and productive elongation. 
(a) mRNAs of HT-144 cells were sequenced after ASOs (5 nM) or pooled siRNAs (50 nM) treatment in 1% 
ITS medium for three days. RNA-Seq data were analyzed with DESeq2 and principal component analysis 
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expressed genes (siSREBF1 group vs siNegative group) in RNA-Seq analysis using Generally Applicable Gene-
set Enrichment (GAGE) method106. Red dash line marks P value = 0.05. (d–f) HT-144 cells were transfected 
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was compared between two treatments for the indicated antibodies at the 5′ promoter region of the SCD gene. 
(g–i) ChIP-qPCR analyses detected DNA pulldown using indicated antibodies at the SCD gene in HT-144 cells. 
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and the RNAP II elongation complex, and the expected DNFA pathways (Supplementary Fig. 10e). We then used 
our RNA-Seq data to divide the overlapping genes into upregulated and downregulated sets, and performed 
GSEA on each. The downregulated genes participate primarily in lipid metabolism pathways (Supplementary 
Fig. 10f), which confirms SREBP1 as a direct activator of DNFA genes. Inflammatory response pathways are 
significantly upregulated in DEGs from RNA-Seq analysis (Fig. 3c), but seem not to be direct targets of SREBP1 
(Supplementary Fig. 10g). We suspect that downregulation of DNFA pathways may change the homeostasis of 
cellular fatty acids and exert further impact on inflammatory response pathways as well as cell death59.
To elucidate the molecular mechanism of SREBP1-governed DNFA gene activation in melanoma cells, we 
used a chromatin immunoprecipitation (ChIP)-qPCR assay to detect occupancy of SREBP1, RNA polymerase 
II (RNAP II), and H3K36me3 – a histone marker associated with transcription elongation60 on DNFA genes. 
SREBP1 depletion by ASO-4 diminished SREBP1, RNAP II and H3K36me3 signals at the SCD promoter 
(Fig. 3d–f). We observed similar (albeit lower-magnitude) results for FASN (Supplementary Fig. 11a–c). These 
ChIP-qPCR results together with the RNA-Seq data (Supplementary Fig. 9e–g) suggest that removal of SREBP1 
at DNFA promoters inhibits transcription activity and mRNA production. We performed ChIP-qPCR analyses 
in SREBP1-activating (1% ITS medium, no lipids) and SREBP1–repressing (10% FBS medium, with lipids) con-
ditions. We found that 1% ITS medium dramatically increases SREBP1 occupancy at the transcription start sites 
(TSS) of SCD (Fig. 3g) and FASN (Supplementary Fig. 11f) in HT-144 cells. The strong RNAP II binding peaks 
at TSS of SCD and FASN in both 10% FBS and 1% ITS culture conditions (Fig. 3h and Supplementary Fig. 11g) 
indicate promoter-proximal pausing of RNAP II61. Furthermore, culturing cells in 1% ITS medium increased 
the occupancy of actively elongating RNAP II (RNAP II S2P) (Supplementary Fig. 11d,i), but not poised RNAP 
II (RNAP II S5P)62 (Supplementary Fig. 11e,j), at the TSS as well as the gene bodies of both SCD and FASN. 
Accordingly, the histone marker H3K36me3 was elevated along both gene bodies in cells cultured with 1% ITS 
(Fig. 3i and Supplementary Fig. 11h). These results suggest that SREBP1 binding near the TSS involves both 
RNAP II recruitment and stimulation of productive elongation on DNFA genes.
Essential role of DNFA in proliferation and survival of untreated and drug-resistant melanoma 
cells. To evaluate the roles DNFA in cell proliferation and survival, we cultured melanoma cells in the lipid-free 
1% ITS medium, using insulin as a growth factor to stimulate proliferation. The metastatic melanoma-derived 
cell lines HT-144 and A375 can proliferate in both 10% FBS and 1% ITS media but remain quiescent in 0% FBS 
medium (Fig. 4a,b). By contrast, the primary melanoma-derived cell line, MEL-JUSO, remains quiescent in both 
lipid-free (1% ITS and 0% FBS) media (Fig. 4c). We depleted SREBF1 with ASO-4 in several melanoma cell lines 
cultured under the three medium conditions, to obtain dose-response curves and IC50 values. We found that 
ASO-4 decreased viability of both proliferative and quiescent cells in all conditions (Fig. 4d–i). We reason that, 
although cancer cells may employ lipid uptake63, DNFA is required for cell survival regardless of external lipid 
availability under conditions similar to those we tested. We observed diminished viability at higher ASO concen-
trations (greater than 5 nM), which correlates with more efficient depletion of SREBP1 and more marked decrease 
of DNFA gene expression (Supplementary Fig. 7g). Comparing the two growth factor-containing culture condi-
tions, we find that ASO-4 is a more potent inhibitor of cell growth/survival in 1% ITS medium than in 10% FBS 
medium with HT-144, A375 and LOXIMVI cells. In contrast, WM1552C, MeWo and MEL-JUSO cells are rela-
tively insensitive to ASO-4 treatment. The implication is that, although DNFA seems to be vital for cell survival, 
medium lipid availability may mitigate the impact of SREBP1 inhibition in cell lines that are sensitive to ASO-4.
BRAF inhibitors (BRAFi, e.g. vemurafenib) improve survival for patients with metastatic melanomas har-
boring the BRAFV600E mutation64. However, the rapid emergence of treatment-surviving tumors limits clinical 
benefits65,66. We derived two BRAFi-resistant cell lines with prolonged vemurafenib treatment: HT-144BR from 
a vemurafenib-sensitive cell line HT-144, and LOXIMVIBR from a vemurafenib-insensitive cell line LOXIMVI 
(Fig. 5a,c). Both HT-144BR and LOXIMVIBR cell lines continuously proliferate in the presence of vemurafenib 
(2 μM). Using cell viability assay, we found that HT-144 and HT-144BR displayed similar sensitivities to ASO-4 
treatment, as did LOXIMVI and LOXIMVIBR (Fig. 5b,d). We reason that these cell lines all depend on SREBP1 
for survival regardless of whether they are sensitive or resistant to vemurafenib.
To confirm that DNFA enzyme inhibition is the crucial driver for reduced cell viability, we then used small 
molecule inhibitors of FASN and SCD enzymes, which reportedly decreased tumor growth in preclinical stud-
ies67–69. In 10% FBS (lipid-containing) medium, FASN and SCD inhibitors decreased viability in both HT-144 
and HT-144BR cells (Fig. 5e,g), although the effect was less potent than SREBF1 depletion by ASO-4. However, 
we observed much stronger effects on cell survival when combining the two inhibitors, confirmed by Bliss inde-
pendence analysis70 as robust positive synergy (Fig. 5f,h). DNFA thus appears vital to melanoma cell survival even 
in vemurafenib-resistant cells.
Continued and elevated DNFA gene expression in melanoma cells after BRAF inhibitor 
treatment. To explore the role of DNFA in BRAFi resistance, we compared DNFA gene expression in 
untreated and vemurafenib-resistant cell lines. We observed modestly higher DNFA gene expression in the 
vemurafenib-resistant HT-144BR and LOXIMVIBR cells as compared with the untreated HT-144 and LOXIMVI 
cells (Fig. 6a,b). We then investigated the short-term impact of vemurafenib on DNFA gene expression in HT-144 
cells treated with various doses of vemurafenib. After one-day treatment, vemurafenib exerted low-dose stimu-
lation and high-dose inhibition of DNFA gene expression, exhibiting hormesis (i.e. bell-shaped dose-response 
curves)71 (Fig. 6c,d, Supplementary Fig. 12a–e). We observed dose–dependent induction of PPARGC1A expres-
sion with vemurafenib treatment (Supplementary Fig. 12f) as expected, given that the BRAF/MEK pathway 
directly suppresses PPARGC1A expression and fatty acid oxidation in melanomas72,73. DNFA inhibition in 
response to high-dose vemurafenib treatment may correlate with onset of cell death, whereas DNFA stimulation 
in response to low-dose vemurafenib treatment suggests rapid cellular resistance.
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To rule out vemurafenib-specific (perhaps off-target) effects, we evaluated dabrafenib, another BRAFi 
employed in clinical practice74. We monitored DNFA gene expression in HT-144 cells after one day treatment 
of dabrafenib. Cell death was less evident after high-dose dabrafenib treatment, perhaps due to lower off-target 
toxicity75. We found that expression of DNFA genes decreased after low-dose dabrafenib treatment but increased 
at effective high-dose treatment (Supplementary Fig. 13a–g). Dabrafenib at 2.5 µM concentration significantly 
stimulated gene expression of ACLY, SCD, ACSL1 and PPARGC1a (Supplementary Fig. 13b,e,f and h).
The effectiveness of BRAF inhibition is widely attributed to downstream inhibition of MEK, and then ERK. 
Resistance due to reactivation of MEK/ERK bypasses that effect. In A375 cells (Supplementary Fig. 14a–h), a cell 
line with reported MEK/ERK reactivation associated with vemurafenib treatment76, vemurafenib exerts little 
induction of DNFA gene expression nor dose–dependent induction of PPARGC1A. An adjuvant ERK inhibitor 
(ERKi, SCH772984) has been employed clinically to overcome vemurafenib resistance77, by directly contributing 
to overall BRAF/MEK/ERK pathway inhibition78. When combining 0.5 μM vemurafenib and 0.5 μM SCH772984 
Figure 4. Reliance on DNFA for melanoma cell survival. (a–c) Cell growth of three melanoma cell lines was 
measured with cell-titer glo assay in 10% FBS, 0% FBS or 1% ITS medium in a time-course experiment. Cell 
proliferation was measured by cell-titer glo assay every day for seven days in three medium conditions. (d–i) 
Melanoma cell lines were transfected with various doses of ASO-4. Cell viability was measured by cell-titer glo 
assay six days after ASO transfection in three medium conditions. ASO-4 treatment diminished viability in 
quiescent cells, which was observed on cells cultured in 0% FBS medium. (a–c) LOXIMVI is the most sensitive 
line to ASO-4 treatment in all three culture conditions, while MEL-JUSO is the least sensitive line.
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for treatment, mimicking clinical practice, we observed induction of DNFA in A375 cells (Supplementary 
Fig. 14i). We saw evidence of a dose-response relationship between ERKi and induction of DNFA gene expression, 
where treatment of SCH772984 at 1 μM achieved stronger induction of DNFA gene expression (Supplementary 
Fig. 14i). Our overall interpretation is that BRAF/MEK/ERK pathway inhibition upregulates DNFA gene expres-
sion, possibly through AKT activation79, which then contributes to vemurafenib tolerance in melanoma cells.
To further characterize the role of SREBP1 and DNFA upregulation in response to BRAF inhibition, we 
combined ASO-4 and vemurafenib treatment in HT-144 cells. We observed that SREBF1 depletion abolished 
the SCD and ASCL1 induction accompanying vemurafenib treatment by RT-qPCR assays (Fig. 6e–g). Finally, 
we investigated cell viability after co-treatment with ASO-4 and vemurafenib. ASO-4, alone or in combina-
tion with vemurafenib, effectively killed HT-144 (Fig. 6h) and A375 cells (Supplementary Fig. 14j). However, 
there is a mild antagonistic effect between ASO-4 and vemurafenib at low doses according to Bliss analysis 
(Fig. 6i, Supplementary Fig. 14k). We regard this as corollary to DNFA stimulation by vemurafenib (Fig. 6e–g, 
Supplementary Fig. 14a–g), while noting that, consistent with our findings above for A375, vemurafenib treat-
ment alone yielded little induction of DNFA gene expression in A375 compared to HT-144, and the antagonistic 
effect was correspondingly lower. In both cell lines, high-dose ASO-4 exerts dominant cell killing effect over 
vemurafenib in combination treatment.
Discussion
Cancers frequently exhibit reprogrammed metabolic traits such as elevated DNFA3 that act to sustain active pro-
liferation and cell survival under adverse conditions, and support the process of tumorigenesis and metastasis, 
as well as resistance to targeted therapies. The diverse genetic paths cancers take to achieve such traits have frus-
trated efforts to exploit them clinically80–82.
Most DNFA enzymes are primarily regulated at the transcriptional level in a coordinated manner6, thus the 
abundance of their mRNAs can be employed as a simple surrogate for DNFA activities. Our results show that 
elevated DNFA gene expression may serve as a prognostic marker for some cancer types, even though they are 
not considered onco-drivers. Moreover, increased DNFA pathway expression appears to be intrinsic to malig-
nant cancer cell types independently of onco-drivers, including constitutively active BRAF mutants. This may be 
consistent with the notion of increased DNFA as an “oncosustenance” pathway, with well-definable mechanistic 
contributions to cancer survival and proliferation. Once the oncosustenance pathway becomes active, it may not 
always matter which onco-drivers acted prior to cancer onset. Indeed, it has already been suggested that malig-
nant cancer cells may have ongoing reliance upon oncogene-induced signaling pathways, but not upon initial 
onco-drivers83. It is also possible that SREBP1 transcription auto-regulation28 might “lock in” elevated DNFA 
expression in malignant cells. The scope of therapeutic investigations, which frequently focus on mutated onco-
genes, could be broadened to include oncosustenance mechanisms.
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Figure 5. DNFA supports survival in drug-resistant melanoma cells. (a,b) HT-144BR is a BRAF inhibitor 
resistant HT-144 cell line, which was derived after prolonged treatment with vemurafenib (2 μM) in 10% FBS 
medium for three months. Viability of HT-144 and HT-144BR cells responding to vemurafenib or ASO4 
treatment in 10% FBS medium was assessed by cell titer-glo assay. (c,d) LOXIMVIBR is the BRAF inhibitor 
resistant LOXIMVI cell line, which was derived after prolonged treatment with vemurafenib (2 μM) in 10% FBS 
medium for three months. Viability of LOXIMVI and LOXIMVIBR cells responding to vemurafenib or ASO-4 
treatment was assessed by cell titer-glo assay in 10% FBS medium. (e–h) HT-144 and HT-144BR cells were co-
treated with FASN inhibitor (FASNi) GSK 2194069 and SCD inhibitor (SCDi) MF-438 in 10% FBS medium 
or 10% FBS medium with vemurafenib (2 μM). (e,g) Cell viability was measured by cell titer-glo assay six days 
after treatment. (f,h) The combination responses for two DNFA enzyme inhibitors were evaluated with the Bliss 
independence model. Positive Bliss scores indicate synergy between two drugs.
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The prevalence of elevated DNFA expression in certain tumor types such as melanoma suggests the presence 
of survival pressure for increased lipogenesis, which may therefore represent a therapeutic linchpin. However, 
high doses of individual pharmacological inhibitors of SCD and FASN enzymes were reportedly required to 
impact cell viability in melanomas and other cancers67,69. This phenomenon may be attributable to compensa-
tory upregulation of SREBP1 and corresponding elevation of DNFA pathway expression, triggered by individual 
DNFA enzyme inhibition84. However, the combined effect of multiple DNFA enzyme inhibitors is synergistic and 
potent, at least in vitro (Fig. 5e–h). We demonstrated in melanomas that inhibition of SREBF1 by 5 nM ASO-4 
treatment results in 50% reduction in the expression of multiple DNFA genes. The potent cell death effect after 
ASO-4 treatment is likely due to the strong synergistic effects of 50% reduction across the entire DNFA enzymatic 
cascade that is coordinately regulated by SREBP1. Therefore, inhibition of multiple DNFA enzymes could be of 
therapeutic benefit due to a potent cumulative effect on lipogenesis, as observed with SREBP1 mRNA-inhibiting 
ASOs and DNFA enzyme-targeting cocktails.
Previous studies have shown that SREBP1 binding and RNAP II recruitment to DNFA gene promoters rep-
resents the primary mechanism for transcription activation85,86. In accord with this, we observed that RNAP II 
accumulated at the proximal promoter regions of SCD and FASN. Under lipid-depleted (SREBP1-activating) cell 
culture conditions, we observed two indications of productive transcription elongation: increased RNAP II with 
serine 2 phosphorylation at its C-terminal domain (RNAPII-S2p)62 and the histone marker for transcription 
elongation (H3K36me3)87 along the gene bodies of FASN and SCD. Based on these findings we suggest a two-step 
working model for regulation of RNAP II machinery: RNAP II recruitment to proximal promoters at lipogenic 
genes, followed by RNAP II release for productive elongation. This model appears to explain elevated and syn-
chronous DNFA gene expression in melanomas, and perhaps other cell types. It is presently unclear exactly how 
RNAP II is released for productive elongation.
BRAF-mutated melanomas are frequently treated with vemurafenib, a targeted therapy to inhibit the onco-
genic BRAF pathway. Because vemurafenib sometimes fails to inhibit MEK/ERK (key targets downstream of 
BRAF)88, current clinical regimens combine inhibitors of both BRAF and MEK and/or ERK for treating metastatic 
melanomas89,90. However, even when combined inhibition is achieved, resistance arises via genetic alterations 
that upregulate the PI3K/AKT pathway91. Our determination that elevated DNFA is mechanistically important 
for resistance to targeted therapies dovetails with a similar recent finding by Talebi et al.92. They reported that 
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Figure 6. Elevated DNFA expression accompanies drug resistance in BRAFi treated melanoma cells. (a) RT-
qPCR assay compared the DNFA gene expression between HT-144 cells in 10% FBS medium and HT-144BR 
cells in 10% FBS medium with vemurafenib (2 μM). (b) RT-qPCR assay compared the DNFA gene expression 
between LOXIMVI cells in 10% FBS medium and LOXIMVIBR cells in 10% FBS medium with vemurafenib 
(2 μM). (c,d) HT-144 cells were treated with different dosages of vemurafenib for 0.5 or 1 day in 1% ITS 
medium. SCD expression was assayed by RT-qPCR analysis. Expression of SCD from all treatment groups was 
normalized to expression under DMSO treatment at day 0.5 (normalized as 1). Relative gene expression was 
compared between 0.5-day and 1-day treatment groups. Data were presented as mean ± SD and quantified 
from triplicates. Two-way ANOVA tests were performed. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. 
(e–g) HT-144 cells were transfected with ASO-4 (5 nM) and then treated with vemurafenib (100 nM) in 1% 
ITS medium for one day. RT-qPCR assay analyzed DNFA gene expression from treatment groups relative to 
expression under ASO-Neg and DMSO treatment at day 1 (normalized as 1). Data are presented as mean ± SD 
and quantified from triplicates. One-way ANOVA tests were performed. ns, not significant; *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001. (h) HT-144 cells were transfected with ASO-4, and then treated in 
combination with vemurafenib. Cell viability was measured by cell titer-glo assay three days after combined 
treatment in 1% ITS medium. (i) The drug interaction in (h) was evaluated with the Bliss independence model.
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SREBP1 processing is downregulated in vemurafenib-responsive cells, while BRAFi-resistant melanoma cells 
maintain SREBP1 processing to protect them from ROS-induced cell death. We find that (1) BRAFi treatment 
is associated with DNFA stimulation in a dose-response relationship and (2) elevated DNFA gene expression is 
a vital survival trait of melanoma cells both before and after they achieve resistance to combined BRAF/MEK 
inhibition. A speculative explanation is that, compared to cells vulnerable to BRAFi treatment, resistant cells 
achieve a state that relies more on DNFA activities and less on BRAF activities. We suspect that increased PI3K/
AKT signaling activates SREBP1 and DNFA for survival in BRAFi-resistant melanoma cells79. There is ongoing 
investigation to demonstrate mechanisms of cell state-related drug resistance.
In summary, our work demonstrates that melanomas engage the DNFA pathway for cell survival – more so 
during drug resistance – and employs SREBP1 to promote transcription activation and elongation of DNFA 
enzyme genes. Although immunotherapy has emerged as a highly promising treatment for a subset of melanoma 
patients93, it may be hampered by significant complications94. SREBP1 and/or DNFA enzyme inhibition may 
represent potential therapeutic alternatives worthy of further exploration for the treatment of melanoma and 
possibly other cancer types characterized by elevated DNFA.
Methods
Cell culture and reagents. The human melanoma cell lines HT-144, MEL-JUSO, LOXIMVI, WM1552C 
and MeWo were kindly provided by C. Benes at MGH. A375 cell line was purchased from American Type Culture 
Collection (ATCC). All melanoma cell lines were regularly maintained and passaged in a humidified incubator 
at 37 °C with 5% CO2, in RPMI-1640 medium (21870092, Thermo Fisher Scientific) supplemented with 10% 
fetal bovine serum95 (Gibco), plus 2 mM L-glutamine (Gibco) and 50 U/ml penicillin-streptomycin (Gibco). 
Two types of lipid-free medium were used for assays: 0% FBS medium contained the RPMI-1640 medium sup-
plemented with 2 mM L-glutamine (Gibco) and 50 U/ml penicillin-streptomycin (Gibco); 1% ITS medium con-
tained the RPMI-1640 medium supplemented with 1 x Insulin-Transferrin-Selenium (ITS-G, Thermo Fisher 
Scientific), 2 mM L-glutamine (Gibco) and 50 U/ml penicillin-streptomycin (Gibco).
The BRAF inhibitor vemurafenib (S1267) and ERK inhibitor SCH772984 (S7101) were purchased from 
Selleck Chemicals. Dabrafenib was kindly provided by R. Corcoran at MGH. SCD inhibitor MF-438 (569406, 
Sigma) and FASN inhibitor GSK 2194069 (5303, Tocris) were dissolved in dimethyl sulfoxide (DMSO) to yield 
50 mM stock solutions for in vitro studies. To generate vemurafenib-resistant cells, parental cells were exposed to 
increasing concentrations of vemurafenib (from 1 μM to 2 μM) for three months. The resistance was confirmed 
by measuring cell viability under vemurafenib treatment.
TCGA data analysis. We analyzed 10,210 TCGA samples from 30 cancer types, for which RNA-Seq 
data were publically available. Briefly, gene-level RNA-Seq expression data (normalized RSEM (RNA-seq by 
expectation-maximization) value) were obtained from cBioportal (http://www.cbioportal.org). For Kaplan-Meier 
plots, RNA-Seq expression data and patient survival data from TCGA all cancers data set (10,210 samples) or 
TCGA skin cutaneous melanoma (SKCM) data set (476 samples) were obtained from UCSC Xena (https://xen-
abrowser.net). To compare gene expression in normal skin tissues and skin tumors (Fig. S2b, c), we used the 
normalized RNA-Seq data of TCGA and GTEx (by TOIL and DESeq2 methods96) from UCSC Xena. To compare 
gene expression with oncogenic mutations in TCGA skin tumor study groups (Supplementary Fig. 4), RNA-Seq 
and oncogene mutation data were obtained and analyzed using CGDS R package97.
Plasmids, siRNAs and ASOs. pcDNA3-Flag-nSREBP1a (plasmid #26801) and pcDNA3-Flag-nSREBP1c 
(plasmid #26802) were purchased from Addgene57. HT-144 cells were transfected with plasmids with 
Lipofectamine 2000 reagent (Thermo Fisher Scientific). The human-specific siRNAs targeting SREBF1 (6720), 
SREBF2 (6721), MED15 (51586) and CREBBP (1387) were pre-designed ON-TARGETplus SMARTpool siRNA 
reagents from Dharmacon. Each ON-TARGETplus SMARTpool siRNA was a mixture of four siRNA duplexes. 
Sequences of individual siRNAs in each SMARTpool reagent were as follows:
siSREBF1-05 (J-006891-05): 5′-GCGCACUGCUGUCCACAAA-3′
siSREBF1-06 (J-006891-06): 5′-GAAUAAAUCUGCUGUCUUG-3′
siSREBF1-07 (J-006891-07): 5′-CGGAGAAGCUGCCUAUCAA-3′
siSREBF1-08 (J-006891-08): 5′-GCAACACAGCAACCAGAAA-3′
siSREBF2-05 (J-009549-05): 5′-GGACAGCGCUCUGGCAAAA-3′
siSREBF2-06 (J-009549-06): 5′-GCACACUGGUUGAGAUCCA-3′
siSREBF2-07 (J-009549-07): 5′-GCAGUGUCCUGUCAUUCGA-3′
siSREBF2-08 (J-009549-08): 5′-GAAAGGCGGACAACCCAUA-3′
siMed15-09 (J-017015-09): 5′-CCAAGACCCGGGACGAAUA-3′
siMed15-10 (J-017015-10): 5′-GGGUGUUGUUAGAGCGUCU-3′
siMed15-11 (J-017015-11): 5′-GGUCAGUCAAAUCGAGGAU-3′
siMed15-12 (J-017015-12): 5′-CCGGACAAGCACUCGGUCA-3′
siCREBBP-06 (J- 003477-06): 5′-GCACAGCCGUUUACCAUGA-3′
siCREBBP-07 (J-003477-07): 5′-UCACCAACGUGCCAAAUAU-3′
siCREBBP-08 (J-003477-08): 5′-GGGAUGAAGUCACGGUUUG-3′
siCREBBP-09 (J-003477-09): 5′-AAUAGUAACUCUGGCCAUA-3′
The negative control siRNAs were the ON-TARGETplus Non-Targeting Pool reagents (D-001810-10, Dharmacon). 
Single-stranded antisense oligonucleotides (ASOs) for SREBF1 were designed and purchased as the locked nucleic 
acid (LNA) gapmers with phosphorothioate bonds from Exiqon. Sequences of individual ASOs were as follows:
1 1Scientific RepoRts |         (2019) 9:10369  | https://doi.org/10.1038/s41598-019-46594-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
ASO-Neg: 5′-+C* + G* + A*A*T*A*G*T*T*A*G*T*A* + G* + C* + G-3′
ASO-1: 5′- + G* + C* + G*C*A*A*G*A*C*A*G*C* + A* + G* + A* + T-3′
ASO-2: 5′- + T* + A* + A*G*G*G*G*A*G*T*T*A* + A* + C* + G* + G-3′
ASO-3: 5′- + T* + A*A*G*G*T*T*T*A*G*A*G* + G* + G* + T* + G-3′
ASO-4: 5′- + C* + T* + T* + A*G*G*G*T*C*A*A*G*A*T* + C* + G-3′
ASO-5: 5′- + C* + A* + G*C*A*G*A*T*T*T*A*T* + T* + C* + A* + G-3′
ASO-6: 5′-+A* + C* + C* + G*T*A*G*A*C*A*A*A* + G* + A* + G* + A-3′
+ indicates a 2′-O, 4′-C-methylene-linked bicyclic ribonucleoside (LNA). * indicates a phosphorothioate 
internucleotide linkage.
siRNAs were suspended in RNase-free 1x siRNA Buffer (Dharmacon) to yield 20 μM stock solutions. ASOs 
were suspended in sterile ddH2O for stock solutions. Melanoma cell lines were transfected with siRNAs or ASOs 
using Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) and the reverse transfection 
protocol suggested by the manufacture. Cells were subjected to immunoblotting or RT-qPCR analyses three days 
after transfection.
Reverse transcription quantitative PCR (RT-qPCR) and RNA-Seq assays. RNAs were isolated from 
cultured cells using the RNeasy Mini Kit (Qiagen). RNAs were treated with RNase-free DNase (Qiagen). RNA 
concentrations were quantified with Qubit RNA BR Assay Kit (Thermo Fisher Scientific). One μg RNAs were 
used for cDNA synthesis with RNA to cDNA EcoDry Premix (TaKaRa) containing both random hexamer and 
oligo(dT)18 primers (Double Primed). qPCR was carried out in triplicates on a LightCycler 480 (Roche) using 
LightCycler 480 SYBR Green I Master (Roche). qPCR primers were designed by MGH primer bank (https://
pga.mgh.harvard.edu/primerbank/) and the primer sequences are listed in Table 1. Relative gene expression was 
calculated with the 2−ΔΔCt method98, and normalized to the 18S housekeeping gene. The mean of negative control 
samples was set to 1.
For RNA-Seq, harvested RNA samples were treated with RNase-free DNase (Qiagen). RNA quality was veri-
fied with RNA ScreenTape (Agilent) on an Agilent 2200 TapeStation (Agilent). mRNAs were isolated from total 
RNAs for library preparation using NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB). RNA-Seq librar-
ies were generated using NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB) and quantified 
using KAPA Library Quantification Kit (KAPABiosystem). Adaptor indexed strand-specific RNA-Seq libraries 
were pooled and sequenced using the pair-end 75-bp per read setting for NextSeq500 High Output v2 Kit (150 
cycles) on the NextSeq 500 sequencer (Illumina).
ACACA forward 5′-ATGTCTGGCTTGCACCTAGTA-3′
ACACA reverse 5′-CCCCAAAGCGAGTAACAAATTCT-3′
ACLY forward 5′-TCGGCCAAGGCAATTTCAGAG-3′
ACLY reverse 5′-CGAGCATACTTGAACCGATTCT-3′
ACSS2 forward 5′-AAAGGAGCAACTACCAACATCTG-3′
ACSS2 reverse 5′-GCTGAACTGACACACTTGGAC-3′
FASN forward 5′-AAGGACCTGTCTAGGTTTGATGC-3′
FASN reverse 5′-TGGCTTCATAGGTGACTTCCA-3′
SCD forward 5′-TCTAGCTCCTATACCACCACCA-3′
SCD reverse 5′-TCGTCTCCAACTTATCTCCTCC-3′
ACSL1 forward 5′-CCATGAGCTGTTCCGGTATTT-3′
ACSL1 reverse 5′-CCGAAGCCCATAAGCGTGTT-3′
SREBF1 forward 5′-ACAGTGACTTCCCTGGCCTAT-3′
SREBF1 reverse 5′-GCATGGACGGGTACATCTTCAA-3′
SREBF2 forward 5′-AACGGTCATTCACCCAGGTC-3′
SREBF2 reverse 5′-GGCTGAAGAATAGGAGTTGCC-3′
HMGCS1 forward 5′-GATGTGGGAATTGTTGCCCTT-3′
HMGCS1 reverse 5′-ATTGTCTCTGTTCCAACTTCCAG-3′
HMGCR forward 5′-TGATTGACCTTTCCAGAGCAAG-3′
HMGCR reverse 5′-CTAAAATTGCCATTCCACGAGC-3′
LDLR forward 5′-ACCAACGAATGCTTGGACAAC-3′
LDLR reverse 5′-ACAGGCACTCGTAGCCGAT-3′
Med15 forward 5′-ATGGACGTTTCCGGGCAAG-3′
Med15 reverse 5′-GCATCCTCGATTTGACTGACCA-3′
CREBBP forward 5′-CAACCCCAAAAGAGCCAAACT-3′
CREBBP reverse 5′-CCTCGTAGAAGCTCCGACAGT-3′
18S forward 5′-GTAACCCGTTGAACCCCATT-3′
18S reverse 5′-CCATCCAATCGGTAGTAGCG-3′
Table 1. The primers used for RT-qPCR assays.
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FASN -2797F 5′-ACCTGCAAGGATGAGAAACG-3′
FASN -2797R 5′-AGCATTGTGTTCGTGTGGAG-3′
FASN -2517F 5′-TCAGGAGCCCAGTCTCTGTC-3′
FASN -2517R 5′-TCTGCCCAGTTCAGAAAGGT-3′
FASN -2275F 5′-TTGCACCCCCAGTGTAAAAT-3′
FASN -2275R 5′-CCTTTGTCTGTGTGGTGTGG-3′
FASN -2061F 5′-CACACATGTCCCCTGGAATC-3′
FASN -2061R 5′-AGGAGGCAGAGGTTGCAGT-3′
FASN -1819F 5′-CTGTTTCCCAGGCTTGTCTAC-3′
FASN -1819R 5′-GTTGGAGACTCGTCCAGCAC-3′
FASN -1556F 5′-GAGGTTTGGAGCATGGAGAG-3′
FASN -1556R 5′-AGGGTCAAGGAAGGACAAGG-3′
FASN -1438F 5′-CCCTGTCTTCCCTTGTCCTT–3′
FASN -1438R 5′-CGCTTCCTTCCTCTCCTGA-3′
FASN -1254F 5′-GCTGAGCCCTCAAAGTAGGA-3′
FASN -1254R 5′-CTCCCTTTTCTGACCGCTTC-3′
FASN -977F 5′-CACACCAGGTGGGTGTCC-3′
FASN -977R 5′-CCCCTCCTTAGCAGCTTCC-3′
FASN -160F (SRE) 5′-CACGAGCATCACCCCACC-3′
FASN -160R (SRE) 5′-TATTTAAACCGCGGCCATCC-3′
FASN -13F (TSS) 5′-TAGAGGGAGCCAGAGAGACG-3′
FASN -13R (TSS) 5′-GCTGCTCGTACCTGGTGAG-3′
FASN 184F 5′–CTCCTCATCCTCCGCTCTC-3′
FASN 184R 5′-CATCCGCCCACCTACTCC-3′
FASN 712F 5′-CAGCCAAGCCTCTGTGAATC-3′
FASN 712R 5′-CTGGTCTGGCCACTTGCAC-3′
FASN 959F 5′-CTGTGGTGTGTGGGTTGGTA-3′
FASN 959R 5′-TCCAACCTGGAGAACCACTC-3′
FASN 1523F 5′-GCCAATACCCTGAACTGAATG-3′
FASN 1523R 5′-CTTCCTCATGTGGCCAGTTC-3′
FASN 1687F 5′-CATGGGTGTCCACCTGTTCT-3′
FASN 1687R 5′-TCTCCGACTCTGGCAGCTT-3′
FASN 1984F 5′-CTGCTGTGCTGTGTCCTCAC-3′
FASN 1984R 5′-CTAGGCCACTCTGGTGCAAT-3′
FASN 2217F 5′-CTTGTTACGGAGGAGCCAAG-3′
FASN 2217R 5′-GGAGCACATCTGGTATGCAA-3′
FASN 2430F 5′-CAAGCTGTGAGTCAGCATGG-3′
FASN 2430R 5′-ACGACCAGATCTGCTGCAC-3′
FASN 2716F 5′-GCAGCTTCCGTCAGAGATTT-3′
FASN 2716R 5′-CGAAGAAGGAGGCATCAAAC-3′
FASN 3802F 5′-TTGGGTGTGAGCGGTTCA-3′
FASN 3802R 5′-AACCTTAGTCTTGGGGTGGG-3′
FASN 4814F 5′-CAGCATCGCACTGGACAC-3′
FASN 4814R 5′-ATCCCCAGCCTCAAGAACTG-3′
FASN 5845F 5′-ACTGCTGCTTTCTCTTTGCC-3′
FASN 5845R 5′-TGTCAGCCTCAGTGCCTC-3′
FASN 6862F 5′-TTTCCTGAGCATGCTGAACG-3′
FASN 6862R 5′-CACCTGCTGCACCTCTGG-3′
FASN 7800F 5′-AGGGGACAGTGCATCAAAGA-3′
FASN 7800R 5′-GCCACTCTATCCTACGGGG-3′
FASN 8819F 5′-CTTATCCAGGCTCCCACGAT-3′
FASN 8819R 5′-GTCCACCTTCTTGAGCTCCT-3′
FASN 9819F 5′-CAGCCGCCATCTACAACATC-3′
FASN 9819R 5′-GAGACTCGGAGCTGGTGTC-3′
FASN 10834F 5′-TGTCACCGCCATCCACAT-3′
FASN 10834R 5′-GTGAGTGCGGCATACTTGG-3′
FASN 11864F 5′-CAAGCTGCCAGAGGACCC-3′
Continued
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Immunoblotting assay. Total cell lysate was prepared with RIPA buffer with protease inhibitors (Protease 
Inhibitor Cocktail Tablets, Roche). Nuclear and cytoplasmic protein fractions were prepared with NE-PER 
Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific). Protein samples were separated on 
the SDS-PAGE gels using 4-15% Mini-PROTEAN TGX Precast Gels (Bio-Rad) and then transferred to pol-
yvinyl difluoride (PVDF) membranes (Immobilon-P, Millipore) for immunoblotting analysis. The following 
primary antibodies were used: mouse anti-SREBP1 (IgG-2A4, BD Biosciences), rabbit anti-FASN (C20G5, 
Cell Signaling), rabbit anti-SCD (23393-1-AP, Proteintech), rabbit anti-ACSL1 (D2H5, Cell Signaling), rabbit 
anti-ACSS2 (D19C6, Cell Signaling), rabbit anti-histone H3 (9715, Cell Signaling) and rabbit anti-actin (13E5, 
Cell Signaling). After being incubated with primary antibodies overnight in PBST solution with 5% non-fat dry 
milk, membranes were probed with HRP-conjugated affinity-purified donkey anti-mouse or anti-rabbit IgG (GE 
Healthcare) and visualized using the Immobilon Western Chemiluminescent HRP Substrate (Millipore).
RNA-Seq and ChIP-Seq analyses. For RNA-Seq, Illumina sequencing reads (FASTQ files) were checked 
with FASTQC for quality control and then aligned to the human genome (GRCh38.86). Genome index genera-
tion and sequence alignment were performed using STAR software99, followed by sorting and indexing of BAM 
files with SAMtools. Raw counts of reads mapped to genes were calculated using HT-Seq100. Differential expres-
sion analysis was performed using DESeq2 R package101. KEGG pathway analysis of differentially expressed gene 
lists and principal component analysis (PCA) were performed using functions within DESeq2. The complete 
RNA-Seq data set has been submitted to the National Center for Biotechnology Information (NCBI) in the Gene 
Expression Omnibus (GEO) database (series entry GSE122707).
SREBP1 ChIP-Seq in multiple cancer cell lines were previously published102. Bam files of SREBP1 and IgG 
control ChIP-Seq from the same cell lines were downloaded from ENCODE (https://www.encodeproject.org). 
SREBP1 binding peaks were called with Model-based Analysis of ChIP-Seq (MACS) and then annotated with 
ChIPseeker R package103. We performed de novo motif analysis of the SREBP1-binding sites with HOMER soft-
ware (http://homer.ucsd.edu/homer/). Overlapping genes between RNA-Seq and ChIP-Seq datasets were iden-
tified by BioVenn104. Pathway annotation network analysis was performed on Cytoscape using ClueGo with 
REACTOME pathway105.
FASN 11864R 5′-CACCTCCACCACCTTCATCT-3′
FASN 12881F 5′-AAGTCCTTCTACGGCTCCAC-3′
FASN 12881R 5′-CCTTCAGAGACTCCACCCAG-3′
FASN 13867F 5′-CCTGCTAGGTATGGAGTTCTCG–3′
FASN 13867R 5′-CGGTGACAGCAGGACAGA-3′
FASN 14857F 5′-TTCTTCAACGAGAGCAGTGC-3′
FASN 14857R 5′-GGAACACCGTGCACTTGAG-3′
FASN 15818F 5′-TTGAGAGATGGCTTGCTGGA-3′
FASN 15818R 5′-GGCTGTCAACAAACCACCTT-3′
FASN 16820F 5′-CATACAGGCCGTCCCCATG-3′
FASN 16820R 5′-AGCACCAGGTTGAGCTCAC-3′
FASN 17838F 5′-CTACGTACTGGCCTACACCC-3′
FASN 17838R 5′-CTCTGAGAGGAAGGAGGGAC-3′
FASN 19809F (TTS) 5′-GTCTGGACCCCGTTTCATTT-3′
FASN 19809R (TTS) 5′-CAGGGAGGAGGGAAGAAAGG-3′
SCD -152F (SRE) 5′-CAGCCCCTTCCAGAGAGAAA-3′
SCD -152R (SRE) 5′-CGAAGGGAATTTGGTGCCAC-3′
SCD 12F (TSS) 5′-GTGGCACCAAATTCCCTTCG-3′
SCD 12R (TSS) 5′-GACACCGACACCACACCA-3′
SCD 245F 5′-CTTGGCAGCGGATAAAAGGG-3′
SCD 245R 5′-GCACGCTAGCTGGTTGTC-3′
SCD 404F 5′-CTTCGAAACCGCAGTCCTC-3′
SCD 404R 5′-CAGGCTGGGAAACTCACATC-3′
SCD 651F 5′-CCGTGAGTTGGGAATGTGGA-3′
SCD 651R 5′-TCACATCCCCACGAAGACAA-3′
SCD 883F 5′-GGAACTTTTCTCCGTTGCGT-3′
SCD 883R 5′-GCCACTCCGCTCTCTAATCA-3′
SCD 1006F 5′-CCACGTGTCTCTTCTCCTGA-3′
SCD 1006R 5′-TTCCAAGTAGAGGGGCATCG-3′
Table 2. The primers used for ChIP-qPCR assays.
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ChIP quantitative PCR (ChIP-qPCR). For each ChIP assay, 5 × 107 cells were used. Chromatins from 
HT-144 cells were fixed with 1% formaldehyde (Polysciences) and prepared with Magna ChIP HiSens Chromatin 
Immunoprecipitation Kit (EMD Millipore). Nuclei were sonicated on a sonic dismembrator 550 (Thermo 
Fisher Scientific) with a microtip (model 419) from Misonix Inc. Lysates were sonicated on ice with 10 pulses 
of 20 sec each (magnitude setting of 3.5) and a 40-sec rest interval. Supernatant was used for immunoprecipi-
tation with the following antibodies: rabbit anti-SREBP1 (H-160, Santa Cruz Biotechnology), rabbit anti-RNA 
Polymerase II (8WG16, BioLegend), rabbit anti-RNA polymerase II CTD repeat YSPTSPS (phospho S2) anti-
body (ab5095, Abcam), rabbit anti-RNA polymerase II CTD repeat YSPTSPS (phospho S5) (ab5131, Abcam), 
rabbit anti-Histone H3 (tri methyl K36) (ab9050, Abcam). qPCR reactions in triplicates were performed on a 
LightCycler 480 (Roche) using LightCycler 480 SYBR Green I Master (Roche). qPCR primers are listed in Table 2.
Cell viability assay and synergy score. For dose-response assay, 1,000 - 2,000 cells were seeded per well 
in Falcon 96-Well Imaging Microplate with Lid (Corning). Cells were then cultured in the absence or presence 
of indicated drugs for 4–6 days. Relative cell viability was quantified with the CellTiter-Glo Luminescent Cell 
Viability Assay Kit (G7572, Promega) and luminescent signals were measured with the Envision 2103 Multilabel 
Microplate Reader (Perkin Elmer). Experiments were performed independently for two or three times. Titration 
curves and IC50 values were generated using GraphPad Prism software. Dose-response data of drug combina-
tions were analyzed with the SynergyFinder R package for synergism70. Synergy scores were calculated across all 
concentration combinations using Loewe or Bliss models.
Code Availability
Scripts used to perform the bioinformatics analyses for this study is available on GitHub https://github.com/
a3609640/DNFA-gene-analysis.
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